{2-[3-(4-bromo-phenyl)-benzo[d]imidazo[1,2-a]imidazol-9-yl]-propyl}-dimethyl-amine | 36994-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: {2-[3-(4-bromo-phenyl)-benzo[d]imidazo[1,2-a]imidazol-9-yl]-propyl}-dimethyl-amine
• 英文别名: 3-[2-(4-bromophenyl)imidazo[1,2-a]benzimidazol-4-yl]-N,N-dimethylpropan-1-amine
• CAS: 36994-25-9
• 化学式: C₂₀H₂₁BrN₄
• 分子量: 397.318
• InChiKey: ZIYVPLKQAPRRCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Compositions and method for treatment of chronic inflammatory diseases
  申请人：Shapiro K. Howard

  公开号：US20050090553A1

  公开（公告）日：2005-04-28

  This invention defines novel compositions that can be used for clinical treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, namely aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clinical disorders addressed herein. Such carbonyl substances are cytotoxic and additionally serve to perpetuate and disseminate the inflammatory process. This invention defines use of compositions, the orally administered required primary agents of which are primary amine derivatives of benzoic acid capable of covalently reacting with the carbonyl substances. p-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed therapeutically effective amount of at least one required primary agent; (2) at least one required previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally one or more additional orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents, so as to produce an additive or synergistic physiological effect of an anti-inflammatory nature.
• US3732243A
  申请人：——

  公开号：US3732243A

  公开（公告）日：1973-05-08